NCT02270814

Cisplatin, Nab-Paclitaxel, and Cetuximab (CACTUX) in Patients With Incurable Head and Neck Squamous Cell Carcinoma

Phase 2 Single Arm Trial of Cisplatin, Nab-Paclitaxel, and Cetuximab (CACTUX) in Patients With Incurable Head and Neck Squamous Cell Carcinoma (HNSCC)

• Status: Active Not Recruiting
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 74 (actual)
• Sponsor: Washington University School of Medicine · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this research study is to look at the effect of a treatment regimen called CACTUX on head and neck cancer. The CACTUX regimen is a combination of three drugs called cisplatin, nab-paclitaxel, and cetuximab (although carboplatin may be given in place of cisplatin if participants have previously had problems receiving cisplatin). The use of nab-paclitaxel in this combination is different from routine care, in which a drug called 5FU is often given instead, but the investigators group has conducted previous research where the investigators incorporated nab-paclitaxel into routine treatment with cisplatin, 5FU, and cetuximab. The investigators are looking at the incidence of side effects with the CACTUX regimen as well as response of the disease and health status.

Conditions

• Head and Neck Cancer
• Head and Neck Squamous Cell Carcinoma
• Cancer of the Head and Neck

Interventions

Type	Name	Description
DRUG	nab-paclitaxel
DRUG	Cisplatin
DRUG	Carboplatin
BIOLOGICAL	Cetuximab

Timeline

• Start date: 2015-02-02
• Primary completion: 2026-06-30
• Completion: 2026-06-30
• First posted: 2014-10-21
• Last updated: 2025-12-30

Locations

5 sites across 1 country: United States

Regulatory

• FDA-regulated drug study